A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Public ClinicalTrials.gov record NCT04009499. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Study identification
- NCT ID
- NCT04009499
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Enrollment
- 1,131 participants
Conditions and interventions
Conditions
Interventions
- Bimekizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 12, 2019
- Primary completion
- May 24, 2026
- Completion
- May 24, 2026
- Last update posted
- Apr 12, 2026
2019 – 2026
United States locations
- U.S. sites
- 31
- U.S. states
- 22
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pa0012 50017 | Phoenix | Arizona | 85037 | — |
| Pa0012 50035 | San Diego | California | 92128 | — |
| Pa0012 50033 | Palm Harbor | Florida | 34684 | — |
| Pa0012 50037 | Tampa | Florida | 33613 | — |
| Pa0012 50039 | Atlanta | Georgia | 30342 | — |
| Pa0012 50024 | Boise | Idaho | 83702 | — |
| Pa0012 50028 | Lexington | Kentucky | 40504 | — |
| Pa0012 50023 | Baton Rouge | Louisiana | 70836 | — |
| Pa0012 50015 | Hagerstown | Maryland | 21740 | — |
| Pa0012 50047 | Boston | Massachusetts | 02115-5817 | — |
| Pa0012 50019 | Lansing | Michigan | 48911 | — |
| Pa0012 50016 | St Louis | Missouri | 63141 | — |
| Pa0012 50005 | Freehold | New Jersey | 07728 | — |
| Pa0012 50029 | Albuquerque | New Mexico | 87102 | — |
| Pa0012 50010 | Brooklyn | New York | 11201 | — |
| Pa0012 50011 | New York | New York | 10029 | — |
| Pa0012 50034 | Rochester | New York | 14642 | — |
| Pa0012 50125 | Charlotte | North Carolina | 28211 | — |
| Pa0012 50031 | Winston-Salem | North Carolina | 27104 | — |
| Pa0012 50040 | Vandalia | Ohio | 45377 | — |
| Pa0012 50020 | Duncansville | Pennsylvania | 16635 | — |
| Pa0012 50006 | Wyomissing | Pennsylvania | 19610 | — |
| Pa0012 50008 | Johnston | Rhode Island | 02919 | — |
| Pa0012 50007 | Orangeburg | South Carolina | 29118 | — |
| Pa0012 50001 | Jackson | Tennessee | 38305 | — |
| Pa0012 50012 | Memphis | Tennessee | 38119-5214 | — |
| Pa0012 50002 | Austin | Texas | 78731 | — |
| Pa0012 50049 | Corpus Christi | Texas | 78404 | — |
| Pa0012 50036 | Mesquite | Texas | 75150 | — |
| Pa0012 50009 | Waco | Texas | 76710 | — |
| Pa0012 50050 | Beckley | West Virginia | 25801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 107 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04009499, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04009499 live on ClinicalTrials.gov.